T PARTNERS 世纪同仁律师事务所 关于南京威尔药业集团股份有限公司 2021 年限制性股票激励计划第二个解除限售期解 除 限 售 条 件 成 就、 调 整 股 票 回 购 价 格 及 回 购 注 销 部 分 限 制 性 股 票 相 关 事 项 的法律意见书 苏 同 律 证 字 (2023) 第 【262】 号 南 京 市 建 邺 区 贤 坤 路 江 岛 智 立 方 Ｃ 座 ４ 层 邮 编 : 210019 电 话： +86 25-83304480 传 真： +86 25-83329335 威尔药业 2021 年限制性股票激励计划 法律意见书 江苏世纪同仁律师事务所 关于南京威尔药业集团股份有限公司 2021 年限制性股票激励计划第二个解除限售期解除限售条件成就、 调整股票回购价格及回购注销部分限制性股票相关事项 的法律意见书 苏同律证字(2023)第【262】号 致:南京威尔药业集团股份有限公司 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民共 和国证券法》(以下简称"《证券法》")、《上市公司股权激励管理办法》(以下 简称"《管理办法》")等法律、法规及规范性文件以及《南京威尔药 ...

公司法》等法律、法规的有关规定向公司提出书面要求，并随附有关证明文件。 证券代码：603351 证券简称：威尔药业 公告编号：2023-040 南京威尔药业集团股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、通知债权人的原因 南京威尔药业集团股份有限公司（以下简称"公司"）于2023 年 8 月11日分别召 开第三届董事会第四次会议及第三届监事会第四次会议，审议通过了《关于回购注 销部分已获授但尚未解除限售的限制性股票的议案》。鉴于公司 2021 年限制性股票 激励计划中 1 名激励对象非履职意外身故，根据《公司 2021 年限制性股票激励计划》 相关规定，其不再满足激励条件，公司将回购注销其已获授但尚未解除限售的 3.93 万股限制性股票。具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn） 及指定媒体披露的《关于调整股票回购价格及回购注销部分限制性股票的公告》 （公告编号：2023-037）。 截至本公告出具日，公司股份总数为 135, ...

证券代码：603351 证券简称：威尔药业 公告编号：2023-035 南京威尔药业集团股份有限公司 第三届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 南京威尔药业集团股份有限公司（以下简称"公司"）第三届董事会第四次会议于 2023 年 8 月 11 日在公司会议室以现场结合通讯方式召开。本次会议通知已于 2023 年8月6 日以书面方式发出。会议由董事长吴仁荣先生主持，应出席董事 7人，实际 出席董事 7 人。本次会议的召集、召开程序符合《公司法》及《公司章程》等相关 规定，会议合法有效。 二、董事会会议审议情况 （一）审议通过了《关于调整 2021 年限制性股票激励计划回购价格的议案》 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）及指定媒体 披露的《关于调整股票回购价格及回购注销部分限制性股票的公告》（公告编号： 2023-037）。 登记的议案》 表决结果：同意 7 票，反对 0 票，弃权 0 票。 （二）审议通过了《关于回购注销部 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603351 证券简称：威尔药业 公告编号：2023-041 南京威尔药业集团股份有限公司 2023 年第二次临时股东大会决议公告 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 14 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 81,593,945 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 60.2265 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，吴仁荣先生主持。会议采用现场投票与网 (一) 股东大会召开的时间：2023 年 8 月 14 日 (二) 股东大会召开的地点：南京市玄武区苏宁大道 64 号徐庄软件园研发五区 5 号楼三楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 络投票相结合的表决方式。本次会议的 ...

证券代码：603351 证券简称：威尔药业 公告编号：2023-038 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京威尔药业集团股份有限公司（以下简称"公司"）于2023 年 8 月11日召开 第三届董事会第四次会议，审议通过了《关于减少公司注册资本、修订<公司章 程>并办理工商变更登记的议案》，具体情况公告如下： 一、 减少公司注册资本的具体情况 二、 修订《公司章程》相关条款等具体情况 根据上述股本变动情况，拟对《公司章程》相关条款进行修订，具体如下： | 序号 | 修订前章程条款 | 修订后章程条款 | | --- | --- | --- | | 1 | 第六条 公 司 注 册 资 本 为 人 民 币 | 第六条 公 司 注 册 资 本 为 人 民 币 | | | 135,478,432 元。 | 135,439,132 元。 | | 2 | 第二十条 公司股份总数为 135,478,432 | 第二十条 公司股份总数为 135,439,132 | | | 股，均为普通股，每股面值人民币1.00 | 股，均 ...

Financial Performance - In 2022, Nanjing Well Pharmaceutical Group achieved a net profit attributable to shareholders of 95.03 million RMB, a decrease of 6.26% compared to 2021[5]. - The company's total revenue for 2022 was approximately 1.11 billion RMB, reflecting a year-on-year increase of 6.59%[22]. - The net profit attributable to shareholders was CNY 95.03 million, a decrease of 6.26% compared to the previous year[33]. - The company reported a net profit of 92.06 million RMB after deducting non-recurring gains and losses, down 6.56% from the previous year[22]. - The company reported basic earnings per share of CNY 0.72, down 5.26% from CNY 0.76 in 2021[23]. - The diluted earnings per share also decreased to CNY 0.71, a decline of 6.58% from the previous year[23]. - The weighted average return on equity was 6.64%, down from 7.63% in 2021, reflecting a decrease of 0.99 percentage points[23]. - The gross profit margin decreased to 27.34%, down by 1.16 percentage points compared to the previous year[55]. - The company achieved a net profit of 300 million RMB, an increase of 20% compared to the previous year[123]. Assets and Liabilities - As of December 31, 2022, the total assets of the company reached approximately 2.14 billion RMB, marking a 16.11% increase from the previous year[22]. - The net assets attributable to shareholders at the end of 2022 were approximately 1.48 billion RMB, up 7.06% from 2021[22]. - The company's short-term borrowings increased by 110.55% to 360,453,327.94 CNY, primarily due to new bank loans[62]. - The total remuneration for the company's directors and senior management during the reporting period amounted to CNY 559.86 million, with no changes in shareholdings reported[122]. Cash Flow - The net cash flow from operating activities for 2022 was approximately 108.99 million RMB, a significant recovery from a negative cash flow in 2021[22]. - The company reported a net cash flow from operating activities of CNY 108,989,026.49, a significant improvement from a negative cash flow in the previous year[52]. - The cash and cash equivalents increased by 33,564,603.83 CNY, reversing a previous decline of 9,295,502.68 CNY[61]. Research and Development - In 2022, the company's R&D expenses amounted to 53.87 million yuan, representing a year-on-year increase of 29.93%, accounting for 4.85% of operating revenue[39]. - The company has 32 ongoing R&D projects, including 4 raw material drug projects, with 10 new projects initiated in 2022[39]. - The company is actively collaborating with pharmaceutical companies to accelerate the R&D of active pharmaceutical ingredients and formulations[36]. - The company has established a provincial-level engineering technology research center for water-soluble pharmaceutical excipients, enhancing its R&D capabilities[68]. - The company reported a significant increase of 201.80% in R&D investment for glycerol ester series products compared to the previous year[74]. Market and Sales - The sales volume of synthetic lubricating base oil increased by 7.42% year-on-year, while sales revenue grew by 1.30%[34]. - The sales volume of pharmaceutical excipients increased by 29.73% year-on-year, with sales revenue rising by 18.87%[35]. - The revenue from pharmaceutical excipients (non-injection) was CNY 197.29 million, with a gross profit margin of 38.04%[55]. - The revenue from the Northeast region was CNY 33.50 million, showing a significant increase of 91.79% year-on-year[55]. - The overseas revenue reached CNY 69.23 million, with a year-on-year increase of 55.91%[55]. Strategic Focus - The company is focusing on strategic emerging industries such as biotechnology and new energy as part of its long-term development plan[33]. - The company is focusing on the development of high-performance lubricants for electric vehicles, driven by the growing demand in the market[46]. - The company aims to enhance its product series in pharmaceutical excipients, focusing on high-standard injectable excipients to increase market share[106]. - The company intends to expand its market presence by optimizing product structures and enhancing customized services in both pharmaceutical excipients and synthetic lubricating oils[107]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements in its reports[6]. - The company faces risks related to product and technology development, including potential mismatches with market demands and regulatory challenges[112]. - The company faces risks related to the quality control of pharmaceutical excipients due to the increasing regulatory scrutiny and the need for continuous improvement in quality control systems as the business scales up[113]. - Environmental protection regulations are becoming stricter, and the company may need to invest more in compliance, potentially increasing operational costs and impacting financial performance[113]. Governance and Compliance - The company has established a governance structure compliant with relevant laws and regulations, ensuring proper operation of the shareholders' meeting, board of directors, and supervisory board[119]. - The company has a risk management system in place that enhances the effectiveness of internal control and management of subsidiaries[152]. - The company has established an internal control system that effectively promotes the steady implementation of its strategy and safeguards the interests of all shareholders[152]. - The company has not faced any penalties from securities regulatory authorities in the past three years[130]. Environmental Responsibility - The company invested CNY 9,123,400 in environmental protection during the reporting period[155]. - The company has implemented various pollution control facilities, with a waste gas treatment capacity of 30,000 m³/h for volatile organic compounds and other pollutants[159]. - The wastewater treatment capacity is 500 tons/day, utilizing multiple advanced processes including SBR and MBR technology[159]. - The company has installed online monitoring equipment for pollutant emissions, ensuring real-time compliance with environmental regulations[163].

Financial Performance - The company's operating revenue for Q1 2023 was ¥246,445,272.15, representing a decrease of 15.19% compared to the same period last year[3] - The net profit attributable to shareholders was ¥26,310,732.19, down by 4.43% year-on-year[3] - The basic earnings per share for the period was ¥0.20, reflecting a decline of 4.76% compared to the previous year[3] - Total operating revenue for Q1 2023 was CNY 246,445,272.15, a decrease of 15.2% compared to CNY 290,586,279.28 in Q1 2022[13] - Net profit for Q1 2023 was CNY 25,635,740.84, a decline of 4.2% from CNY 26,763,211.11 in Q1 2022[14] - The net profit attributable to the parent company for Q1 2023 was CNY 26,310,732.19, a decrease of 4.4% compared to CNY 27,529,731.11 in Q1 2022[15] - The total operating revenue from sales of goods and services in Q1 2023 was CNY 192,568,787.82, a decline of 9.4% from CNY 212,565,168.83 in Q1 2022[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,222,032,915.04, an increase of 3.92% from the end of the previous year[4] - Total assets as of March 31, 2023, were CNY 2,222,032,915.04, an increase from CNY 2,138,160,094.23 at the end of 2022, marking a growth of 3.9%[12] - Total liabilities increased to CNY 701,845,128.22 from CNY 655,756,145.87 at the end of 2022, representing a rise of 7%[12] - Non-current assets totaled CNY 1,695,214,247.90, up from CNY 1,667,874,751.61 at the end of 2022, indicating a growth of 1.6%[11] Cash Flow - The net cash flow from operating activities was negative at -¥12,432,495.15, indicating a significant decline in cash generation[3] - The net cash flow from operating activities for Q1 2023 was negative at CNY -12,432,495.15, compared to a positive CNY 9,037,458.54 in Q1 2022[18] - The company incurred a total cash outflow from operating activities of CNY 207,996,715.51 in Q1 2023, slightly higher than CNY 205,447,864.92 in Q1 2022[18] - The net cash outflow from investing activities for Q1 2023 was CNY -31,422,829.04, compared to CNY -8,785,815.73 in Q1 2022[19] - The company reported cash inflows from financing activities of CNY 125,600,000.00 in Q1 2023, an increase from CNY 115,370,000.00 in Q1 2022[19] - The company reported a net cash inflow from financing activities of CNY 72,635,872.05 in Q1 2023, compared to CNY 66,972,377.01 in Q1 2022[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,087[6] - The top shareholder, Wu Renrong, holds 13.67% of the shares, with 10,890,000 shares pledged[7] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 214,807,670.05, down 16.6% from CNY 257,641,185.97 in Q1 2022[14] - The company reported R&D expenses of CNY 12,944,144.72 for Q1 2023, an increase of 19.3% compared to CNY 10,847,878.76 in Q1 2022[14] Inventory and Receivables - Cash and cash equivalents increased to CNY 128,322,164.94 as of March 31, 2023, compared to CNY 99,827,619.02 at the end of 2022, representing a growth of 28.5%[11] - Accounts receivable rose to CNY 152,574,670.50, slightly up from CNY 151,137,005.14 at the end of 2022, indicating a 1% increase[11] - Inventory increased to CNY 185,884,308.49, up from CNY 165,129,389.22 at the end of 2022, reflecting a growth of 12.5%[11] Borrowings - Long-term borrowings increased by 42.54%, attributed to new bank loans during the reporting period[5] Miscellaneous - The weighted average return on equity decreased by 0.21 percentage points to 1.76%[3] - The company did not report any net profit from the merged entity in the current or previous period[16]

证券代码：603351 证券简称：威尔药业 公告编号：2023-016 南京威尔药业集团股份有限公司关于 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 05 月 05 日 下午 14:00-15:00 召开 2022 年度暨 2023 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 04 月 25 日至 05 月 04 日 16:00 前登录上证路演中心 网站首页点击"提问预征集"栏目或通过公司邮箱 wellyy@well-js.com 进行提 问。公司将在说明会上对投资者普遍关注的问题进行回答。 一、说明会类型 南京威尔药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 25 日发布公司 2022 年度报告及 2023 年第一季度报告，为便于广大投资者更全面深 入地了解公司公司经营成果、财务状况，公司拟召开 2022 年度暨 2023 年第一季 度网上业绩说明会，针对 2022 年度及 2023 年第一季度的经营成果及 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥262,865,410.62, a decrease of 5.92% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2022 was ¥17,789,152.14, down 34.94% year-over-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥16,270,113.68, a decline of 38.46% compared to the previous year[3]. - The basic earnings per share for Q3 2022 was ¥0.13, reflecting a decrease of 38.10% year-over-year[4]. - The net profit for Q3 2022 was CNY 77,248,178.32, a decrease of 7.4% compared to CNY 83,384,566.77 in Q3 2021[18]. - The operating profit for Q3 2022 was CNY 88,142,528.77, down 21.9% from CNY 112,796,265.16 in Q3 2021[18]. - The total comprehensive income for Q3 2022 was CNY 77,248,178.32, down from CNY 83,384,566.77 in Q3 2021[19]. - Basic and diluted earnings per share for Q3 2022 were CNY 0.59, a decrease from CNY 0.64 in Q3 2021[19]. Revenue and Costs - Total revenue for the first three quarters of 2022 reached ¥850,975,692.57, an increase of 11.4% compared to ¥764,195,246.66 in the same period of 2021[17]. - Total operating costs for the first three quarters of 2022 were ¥764,101,966.80, up from ¥652,384,213.26 in 2021, reflecting a year-on-year increase of 17.1%[17]. Assets and Liabilities - The total assets as of September 30, 2022, amounted to ¥2,081,052,946.01, representing a 13.01% increase from the end of the previous year[4]. - The total assets of the company reached ¥2,081,052,946.01, up from ¥1,841,426,562.78 at the end of 2021, reflecting a growth of 13.0%[15]. - The company reported a significant increase in total liabilities to ¥618,779,501.63 as of September 30, 2022, compared to ¥456,012,175.77 at the end of 2021, representing a rise of 35.6%[14]. - The company’s total liabilities increased, with a significant rise in borrowings to CNY 360,870,000.00 in Q3 2022 from CNY 170,559,040.00 in Q3 2021[23]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥40,452,488.32[3]. - The cash flow from operating activities for the first three quarters of 2022 was CNY 40,452,488.32, a significant improvement from a negative cash flow of CNY -78,272,989.21 in the same period of 2021[22]. - The company reported a net cash outflow from investing activities of CNY -175,558,816.01 for the first three quarters of 2022, compared to CNY -20,337,564.19 in the same period of 2021[22]. - The cash and cash equivalents at the end of Q3 2022 were CNY 65,576,292.39, down from CNY 90,783,659.51 at the end of Q3 2021[23]. - The company's cash and cash equivalents as of September 30, 2022, were ¥65,576,292.39, slightly down from ¥66,263,015.19 at the end of 2021[12]. Shareholder Information - The top ten shareholders collectively hold 70.77% of the company's shares, with the largest shareholder holding 13.67%[9]. Expenses - The company reported a significant increase in management expenses, contributing to the decline in net profit[6]. - Research and development expenses for the first three quarters of 2022 were ¥36,992,312.72, slightly up from ¥34,926,014.04 in 2021, indicating a focus on innovation[17]. Government Support - The company received government subsidies amounting to ¥2,207,000.00 during the reporting period[6]. Accounts Receivable and Inventory - Accounts receivable increased to ¥148,418,923.32 as of September 30, 2022, compared to ¥120,214,744.95 at the end of 2021, representing a growth of 23.4%[12]. - Inventory levels rose to ¥170,594,791.16, up from ¥142,442,042.74 in 2021, indicating a year-on-year increase of 19.8%[13]. Borrowings - Short-term borrowings surged to ¥328,383,358.80 as of September 30, 2022, compared to ¥171,193,229.29 at the end of 2021, marking an increase of 91.9%[14].

Financial Performance - The company's operating revenue for the first half of 2022 was RMB 588,110,281.95, representing a 21.31% increase compared to RMB 484,789,805.14 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was RMB 60,762,416.76, which is a 7.55% increase from RMB 56,498,039.97 in the previous year[18]. - The net cash flow from operating activities was RMB 9,437,590.82, a significant improvement from a negative cash flow of RMB -56,032,897.92 in the same period last year, marking a 116.84% change[18]. - The total assets at the end of the reporting period were RMB 2,032,084,113.47, reflecting a 10.35% increase from RMB 1,841,426,562.78 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company increased to RMB 1,419,147,128.45, a 2.64% rise from RMB 1,382,705,623.96 at the end of the previous year[18]. - The basic earnings per share for the first half of 2022 was RMB 0.45, up 4.65% from RMB 0.43 in the same period last year[19]. - The weighted average return on net assets was 4.30%, slightly up from 4.28% in the previous year, indicating a marginal improvement[20]. Revenue and Sales Growth - Sales volume of synthetic lubricating base oil increased by 16.45% compared to the same period last year, with sales revenue growing by 16.22%[32]. - The sales volume of pharmaceutical excipients grew by 37.74% year-on-year, with sales revenue increasing by 32.13%[33]. - The company achieved a revenue of 588.11 million yuan in the first half of 2022, representing a year-on-year growth of 21.31%[31]. Research and Development - Research and development expenses rose by 20.63% to approximately ¥24.46 million, reflecting the company's commitment to innovation and increased investment in R&D[38]. - The company established a new application development center and a technology transformation platform of 1,600 square meters to enhance its R&D capabilities[36]. - The company has 16 ongoing projects in R&D, with 6 new projects initiated and 5 new products registered with the CDE[36]. Market and Industry Trends - The pharmaceutical industry is experiencing a shift towards domestic excipients due to rising prices and supply shortages of raw materials, leading to a reshaping of the industry[33]. - The company is focusing on expanding its market presence in response to the demand for COVID-19 related pharmaceutical excipients[33]. - The company is actively participating in the development of low-carbon emission technologies in response to national carbon neutrality goals, which presents new opportunities for synthetic lubricating base oil innovation[28]. Financial Position and Assets - The total liabilities rose to CNY 611,184,134.65 from CNY 456,012,175.77, which is an increase of approximately 34.0%[116]. - Total current assets increased to CNY 517,008,123.30 from CNY 464,691,328.94, representing a growth of approximately 11.5%[114]. - Cash and cash equivalents rose significantly to CNY 133,205,087.81, up from CNY 66,263,015.19, marking an increase of about 100.7%[114]. Risks and Challenges - The company has outlined potential risks in its management discussion, emphasizing the importance of investor awareness regarding future plans and strategies[7]. - The company faces risks related to product and technology development, particularly in meeting safety and regulatory standards for pharmaceutical excipients[47]. - Fluctuations in the prices of key raw materials, such as ethylene oxide and propylene oxide, could impact production costs and overall financial performance[48]. Shareholder and Governance - The company has not proposed any profit distribution or capital reserve transfer for the half-year period[53]. - The controlling shareholders committed to a 36-month lock-up period for their shares post-IPO, with an automatic extension of 6 months if the stock price falls below the issue price for 20 consecutive trading days within the first 6 months[67]. - The company has established strict compliance with relevant laws and regulations regarding shareholding and transfer[75]. Environmental and Compliance - The company has established an environmental management system certified by ISO 14001, ensuring compliance with local environmental standards[63]. - The company's subsidiary, Weir Bio-Tech, is classified as a key pollutant discharge unit, with no exceedance of pollutant discharge limits reported during the reporting period[57]. - Weir Bio-Tech has implemented various pollution control facilities, with treatment capacities ranging from 1,000 m³/h to 30,000 m³/h, all operating normally[58][59].